Equillium, Inc. (EQ)
Largest Insider Buys in Sector
EQ Stock Price History Chart
EQ Stock Performance
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Activity of Equillium, Inc.
Over the last 12 months, insiders at Equillium, Inc. have bought $0 and sold $79,933 worth of Equillium, Inc. stock.
On average, over the past 5 years, insiders at Equillium, Inc. have bought $0 and sold $786,589 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Equillium, Inc.
| 2024-11-14 | Sale | Chief Financial Officer | 10,000 0.0286% | $0.70 | $7,000 | +1.37% | ||
| 2024-10-28 | Sale | Sr. Vice President and COO | 15,000 0.0481% | $1.25 | $18,750 | 0.00% | ||
| 2024-10-28 | Sale | Principal Accounting Officer | 2,835 0.0091% | $1.25 | $3,544 | +10.00% | ||
| 2024-10-25 | Sale | Principal Accounting Officer | 683 0.0022% | $1.25 | $854 | 0.00% | ||
| 2024-09-26 | Sale | Chief Financial Officer | 10,000 0.0286% | $0.81 | $8,100 | 0.00% | ||
| 2024-09-16 | Sale | Principal Accounting Officer | 38,806 0.1083% | $0.85 | $32,985 | -10.47% | ||
| 2024-07-16 | Sale | Chief Financial Officer | 10,000 0.0368% | $0.87 | $8,700 | -10.11% | ||
| 2022-08-29 | Sale | Chief Financial Officer | 7,000 0.0202% | $2.83 | $19,810 | -68.77% | ||
| 2022-06-06 | Sale | Chief Financial Officer | 5,000 0.0147% | $2.52 | $12,600 | -34.00% | ||
| 2022-04-04 | Sale | Chief Financial Officer | 8,000 0.0228% | $3.18 | $25,440 | -41.54% | ||
| 2021-12-01 | Sale | Chief Financial Officer | 5,000 0.0181% | $5.08 | $25,402 | -45.48% | ||
| 2021-11-16 | Sale | Sr. Vice President and COO | 11,434 0.0391% | $5.49 | $62,715 | -50.09% | ||
| 2021-10-06 | Sale | Chief Scientific Officer | 8,092 0.0282% | $7.01 | $56,706 | -54.17% | ||
| 2021-09-27 | Sale | Chief Financial Officer | 8,000 0.0271% | $6.74 | $53,924 | -51.85% | ||
| 2021-07-27 | Sale | Chief Financial Officer | 5,000 0.0167% | $5.72 | $28,585 | -32.45% | ||
| 2021-06-08 | Sale | Chief Scientific Officer | 10,495 0.0339% | $7.18 | $75,315 | -37.70% | ||
| 2021-06-07 | Sale | Chief Scientific Officer | 22,390 0.074% | $7.12 | $159,409 | -35.76% | ||
| 2021-06-04 | Sale | Chief Scientific Officer | 13,539 0.0471% | $7.01 | $94,846 | -30.52% | ||
| 2021-05-26 | Sale | Chief Financial Officer | 5,000 0.0171% | $6.50 | $32,484 | -20.92% | ||
| 2020-12-28 | Sale | Chief Scientific Officer | 25,000 0.1048% | $4.52 | $113,045 | +37.96% |
Institutional Investor Ownership
| The Vanguard Group | $1.94M | 2.39 | 841,948 | +0.6% | +$11,591.58 | <0.0001 | |
| GOLDEN CAPITAL MANAGEMENT LLC | $1.3M | 1.6 | 562,278 | 0% | +$0 | 3.44 | |
| Renaissance Technologies | $483,000.00 | 0.59 | 209,200 | -39.8% | -$319,306.41 | <0.01 | |
| Geode Capital Management | $461,456.00 | 0.57 | 199,728 | +15.86% | +$63,169.25 | <0.0001 | |
| Acadian Asset Management | $249,000.00 | 0.31 | 108,691 | New | +$249,000.00 | <0.01 | |
| Callan Capital | $230,279.00 | 0.28 | 99,688 | 0% | +$0 | 0.02 | |
| State Street | $121,552.00 | 0.15 | 52,620 | -6.4% | -$8,315.99 | <0.0001 | |
| JPMorgan Chase | $115,599.00 | 0.14 | 50,043 | -85.7% | -$692,970.30 | <0.0001 | |
| Jane Street Capital | $96,456.00 | 0.12 | 41,756 | +246.81% | +$68,643.70 | <0.0001 | |
| American Century Investments | $93,167.00 | 0.11 | 40,332 | New | +$93,167.00 | <0.0001 | |
| Integrated Wealth Concepts Llc | $92,400.00 | 0.11 | 40,000 | 0% | +$0 | <0.01 | |
| Northern Trust | $80,963.00 | 0.1 | 35,049 | -0.3% | -$244.86 | <0.0001 | |
| Prudential Financial | $72,072.00 | 0.09 | 31,200 | -52.29% | -$79,002.00 | <0.0001 | |
| Prelude Capital | $35,805.00 | 0.04 | 15,500 | New | +$35,805.00 | <0.01 | |
| Susquehanna International Group | $33,851.00 | 0.04 | 14,654 | New | +$33,851.00 | <0.0001 | |
| Marshall Wace | $27,483.00 | 0.03 | 11,897 | New | +$27,483.00 | <0.0001 | |
| Ground Swell Capital Llc | $26,410.00 | 0.03 | 11,433 | New | +$26,410.00 | 0.03 | |
| Stifel | $23,375.00 | 0.03 | 10,119 | New | +$23,375.00 | <0.0001 | |
| Tower Research Capital | $16,999.00 | 0.02 | 7,359 | -21.56% | -$4,673.05 | <0.0001 | |
| Simplex Trading Llc | $11,000.00 | 0.02 | 5,155 | New | +$11,000.00 | <0.0001 | |
| BlackRock | $8,803.00 | 0.01 | 3,811 | -0.31% | -$27.72 | <0.0001 | |
| Wells Fargo | $2,659.00 | <0.01 | 1,151 | +0.17% | +$4.62 | <0.0001 | |
| Citadel Advisors LLC | $707.00 | <0.01 | 306 | -99.51% | -$144,849.51 | <0.0001 | |
| Royal Bank of Canada | $0 | <0.01 | 29 | -79.72% | -$0 | <0.0001 |